Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BIO-TECHNE (TECH) Equity Average: 2010-2025

Historic Equity Average for BIO-TECHNE (TECH) over the last 15 years, with Sep 2025 value amounting to $1.9 billion.

  • BIO-TECHNE's Equity Average fell 7.67% to $1.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 billion, marking a year-over-year decrease of 7.67%. This contributed to the annual value of $2.0 billion for FY2025, which is 1.18% down from last year.
  • Per BIO-TECHNE's latest filing, its Equity Average stood at $1.9 billion for Q3 2025, which was down 1.33% from $2.0 billion recorded in Q2 2025.
  • BIO-TECHNE's Equity Average's 5-year high stood at $2.1 billion during Q4 2024, with a 5-year trough of $1.5 billion in Q1 2021.
  • Its 3-year average for Equity Average is $2.0 billion, with a median of $2.0 billion in 2023.
  • Its Equity Average has fluctuated over the past 5 years, first climbed by 17.75% in 2021, then dropped by 7.67% in 2025.
  • Over the past 5 years, BIO-TECHNE's Equity Average (Quarterly) stood at $1.7 billion in 2021, then grew by 6.82% to $1.8 billion in 2022, then rose by 10.70% to $2.0 billion in 2023, then grew by 6.46% to $2.1 billion in 2024, then dropped by 7.67% to $1.9 billion in 2025.
  • Its Equity Average was $1.9 billion in Q3 2025, compared to $2.0 billion in Q2 2025 and $2.0 billion in Q1 2025.